AMPHAMPHHealthcare · Drug Manufacturers - Specialty & Generic

AMPH Stock Forecast: Amphastar Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 18 Nov 2026
$30
+2.10% on the day

The 7 Wall Street analysts covering Amphastar Pharmaceuticals, Inc. hold a median 12-month price target of $24 — -19.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 17 Nov 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$1.2B
Ticker Nerd rank
94/ 100
Median analyst target
$24
Analysts covering
7
Revenue$183.9M+5.4% y/y
Operating income$39.7M
Net income$30.3M
Free cash flow$42.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.9%
1M
+14.8%
YTD
+10.9%
1Y
+14.7%
From 52W high
0.0%
From 52W low
+76.1%
$17
$30
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AMPH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Amphastar Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Nov 2026
94/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
98
Volatility
89
Revisions
82
Quality
74
Issuance
71
Growth
65
Momentum
63
Accruals
58
Size
40

Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (58): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (40): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

AMPH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AMPH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$18$20$22$24$26$28$30Jan 26Apr 26Jul 26Oct 26AMPHHigh $30Median $24Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
0 Buy6 Hold1 Sell
Low $20Median $24High $30

The green dot is the last close — the median target sits −19.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
6 Nov 2026Wells FargoMaintainsEqual-Weight$20 → $25
18 Aug 2026BarclaysMaintainsEqual-Weight$20 → $23
18 Aug 2026BarclaysMaintainsEqual-Weight—
7 Aug 2026Piper SandlerMaintainsNeutral$21 → $20
7 Aug 2026Piper SandlerMaintainsNeutral—
7 Aug 2026Wells FargoMaintainsEqual-Weight—
7 Aug 2026Wells FargoMaintainsEqual-Weight$19 → $20
29 June 2026B of A SecuritiesDowngradeUnderperform$25 → $20
29 June 2026B of A SecuritiesDowngradeUnderperform—
3 June 2026BarclaysMaintainsEqual-Weight—
14 May 2026Wells FargoDowngradeEqual-Weight—
11 May 2026Piper SandlerReiteratesNeutral—
8 May 2026NeedhamDowngradeHold—
21 Apr 2026JefferiesDowngradeHold—
8 Apr 2026BarclaysMaintainsEqual-Weight—
27 Feb 2026NeedhamMaintainsBuy—
27 Feb 2026Wells FargoMaintainsOverweight—
9 Dec 2025BarclaysInitiatesEqual-Weight—
7 Nov 2025NeedhamMaintainsBuy—
22 Oct 2025NeedhamReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

AMPH appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

AMPH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Nov 2026, Amphastar Pharmaceuticals, Inc. returned +14.7% against +12.2% for the S&P 500, dividends included.

AMPH vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120Jan 26Apr 26Jul 26Oct 26AMPHS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AMPH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+7.8%
Analysts raising
4
Analysts cutting
0
Fundamentals

Amphastar Pharmaceuticals, Inc. (AMPH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
13.4×

Cheaper than 49% of US stocks

Price / sales
1.7×

Cheaper than 55% of US stocks

Price / book
1.5×

Cheaper than 51% of US stocks

EV / EBITDA
8.6×

Cheaper than 42% of US stocks

Growth & margins
Revenue growth (YoY)
8.2%

Higher than 49% of US stocks

Earnings growth (YoY)
117.7%

Higher than 86% of US stocks

Gross margin
50.8%

Higher than 63% of US stocks

Operating margin
18.7%

Higher than 79% of US stocks

Net margin
13.3%

Higher than 75% of US stocks

Returns & dividend
Return on equity
12.4%

Higher than 69% of US stocks

Return on assets
5.2%

Higher than 77% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Amphastar Pharmaceuticals, Inc. (AMPH) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Amphastar Pharmaceuticals, Inc. has a market value of $1.2B and an enterprise value of $1.7B.

  • Revenue in the twelve months to 30 June 2026: $730.0M. The latest quarter grew 8.2% year on year.

  • Net income over the same four quarters: $78.5M, a 10.8% net margin.

  • Diluted earnings per share, trailing twelve months: $1.69.

  • Free cash flow in the twelve months to 30 June 2026: $152.9M.

  • Amphastar Pharmaceuticals, Inc. spent $100.1M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 42.5M.

  • Trailing P/E: 13.4×; forward P/E: 8.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Amphastar Pharmaceuticals, Inc. employs 1,976 people — $369K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 17 Nov 2026

Data provided by Twelve Data

Peers

AMPH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
AMPHAmphastar Pharmaceuticals, Inc.$1.2B94
PAHCPhibro Animal Health Corp.$1.4B92
PCRXPacira Biosciences, Inc.$1.5B100
HROWHarrow, Inc.$1.1B42
ALVOAlvotech$1.6B32
ANIPANI Pharmaceuticals, Inc.$1.6B98
ETONEton Pharmaceuticals, Inc.$1.8B99

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Amphastar Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AMPH news & analysis

Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London

PRNewsWire · 11 Nov 2026neutral

Amphastar Pharmaceuticals announced that CFO Bill Peters and EVP of Corporate Administration Jacob Liawatidewi will participate in an analyst-moderated fireside chat at the Jefferies Global Healthcare Conference in London on November 18, 2026, at 12:00 p.m. GMT.

Why it matters — AMPH watchers may note the scheduled conference appearance by two company executives.

Amphastar Pharmaceuticals, Inc. (AMPH) Q3 2026 Earnings Call Transcript

Seeking Alpha · 6 Nov 2026neutral

Amphastar Pharmaceuticals held its third-quarter 2026 earnings call on November 5, 2026, with CFO William Peters and other company representatives participating. The excerpt contains opening remarks and a forward-looking-statement notice, but no financial results or business updates.

Why it matters — The call is a source of company commentary, though this excerpt does not provide substantive operating or financial details for AMPH watchers to assess.

Amphastar (AMPH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Investment Research · 6 Nov 2026neutral

Zacks Investment Research says Amphastar’s Q3 headline results for the quarter ended September 2026 provide a view of performance, while noting that key metrics can also be compared with Wall Street estimates and year-ago actuals.

Why it matters — Those comparisons offer AMPH watchers additional context for assessing the quarter’s results.

Amphastar Pharmaceuticals Q3 Earnings Call Highlights

MarketBeat · 6 Nov 2026positive

Amphastar Pharmaceuticals reported record third-quarter revenue of $207.6 million, up 8% year over year. BAQSIMI and Primatene MIST sales and newer-product contributions offset manufacturing disruptions and lower pricing on some established medicines.

Why it matters — The results highlight growth in newer and key product sales alongside ongoing manufacturing and pricing pressures.

Amphastar Pharmaceuticals (AMPH) Tops Q3 Earnings and Revenue Estimates

Zacks Investment Research · 5 Nov 2026positive

Amphastar Pharmaceuticals reported quarterly earnings of $1.14 per share, exceeding the Zacks Consensus Estimate of $0.78. Earnings were $0.93 per share a year earlier.

Why it matters — The results show Amphastar’s reported quarterly earnings surpassed the consensus estimate and the year-ago figure.

FAQ

Frequently asked questions about AMPH stock

What is the AMPH stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Amphastar Pharmaceuticals, Inc. have a median 12-month price target of $24, with estimates ranging from $20 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AMPH stock a buy right now?

Of the 7 analysts covering Amphastar Pharmaceuticals, Inc., 0 rate it a Buy, 6 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Amphastar Pharmaceuticals, Inc. 94 out of 100 across roughly 4,600 US stocks as at 17 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AMPH?

As at 17 Nov 2026, Amphastar Pharmaceuticals, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).

Will AMPH stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies -19.2% from the last close, and Ticker Nerd's factor model ranks Amphastar Pharmaceuticals, Inc. 94 out of 100 as at 17 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AMPH stock forecast for 2030?

No analyst covering Amphastar Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AMPH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $30 over the next 12 months.

How has AMPH stock performed over the past year?

Amphastar Pharmaceuticals, Inc. returned +14.7% over the 12 months to 18 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Amphastar Pharmaceuticals, Inc. do?

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that develops, manufactures, and markets technically challenging generic and proprietary injectable, inhalation, and intranasal products.

What is the latest news on AMPH?

The most recent item we track (PRNewsWire, 11 Nov 2026): "Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London". Amphastar Pharmaceuticals announced that CFO Bill Peters and EVP of Corporate Administration Jacob Liawatidewi will participate in an analyst-moderated fireside chat at the Jefferies Global Healthcare Conference in London on November 18, 2026, at 12:00 p.m. GMT.

Company

About Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that develops, manufactures, and markets technically challenging generic and proprietary injectable, inhalation, and intranasal products. Amphastar Pharmaceuticals, Inc. also supplies active pharmaceutical ingredient products, including insulin APIs, supporting both its own finished medicines and external customers. Its portfolio includes prescription and over-the-counter treatments used in hospital, urgent care, and retail pharmacy settings, with products addressing areas such as respiratory care, allergic reactions, anticoagulation, opioid overdose reversal, and diagnostic support. The company operates through its Pharmaceutical Products segment and emphasizes complex drug delivery systems, biologics, and biosimilar capabilities. Amphastar Pharmaceuticals, Inc. serves healthcare providers, distributors, and patients across the United States and selected international markets.

CEO Dr. Yongfeng Zhang Ph.D. · 1,976 employees · United States · https://www.amphastar.com